GTC Biotherapeutics (fka GTCB)

[jessellivermore]

graduatestudent''

My point is.....we just do not know the circumstances and answers to many {most) of the issues raised on this board. You don't know them and neither do I. You might be surprised about how Cox feels about his options....you are assuming GTCB's chances for success are pretty slim,,,at least it sounds that way from your comments. We know Cox has more than 600,000 options, if the company survives the next 18 months we know it will have achieved a self sustaining revenue stream. If Atryn can be shown to improve surival in DIC, GTCB will be in control of a blockbuster drug. GTCB can look forward to revenues from FVIIa (the only stuff on the planet worth more is Kryptonite). I would put the chances of those things coming to pass way above 70% At that point the PPS would be way above 20....and Cox's options would be worth more than 12,000,000$ Roughly twenty years salary.

Things have been rough lately,,,,it's mainly a cash situation..
GTCB has been in worse straights in the past. After the EMEA debacle the future of Atryn and even GTCB's platform was teetering on the abiss. If they had not gotten a reversal who knows what might of happened and they close to being out of money then. I talked to Cox at the shareholder after the negative opinion,,,,it was a really dark time..I got the sense then of his determination that he was a good CEO for the company.

The one area the company could talk up more would be what type of effort they are putting into an agreement with Japan. Japan already believes AT3 is effective in DIC...They should be pushing this hard,